8.17.09
Human Genome Sciences (HGS; Rockville, MD) credits EDC technology from DSG (Malvern, PA) for helping the company meet the primary endpoint in two Phase III trials of its Lupus drug BENLYSTA.
The study, BLISS-52, utilized DSG's eCaseLink EDC software to capture data and support data management in their Herculean task of monitoring the nearly 400 electronic case report forms per subject.
“This was our first experience with EDC, and DSG really helped lead the way," said Pierre Verroye, Executive Director of Clinical Data Management and Clinical Programming, HGS, in a company press release. "Sites and CRAs gave us a lot of positive feedback about the eCaseLink system.”
If BENLYSTA is approved, it will be the first drug approved in decades for people living with systemic lupus.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.